Clinical Trial Update: Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the absorption, distribution, metabolism, and excretion of [14C]-labelled BIA 3-202 and its metabolites in Parkinson's disease; the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BIA 3-202

Snippet

Sponsor: Bial - Portela C S.A. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED